Gilead Sciences (GILD): financials, SEC filings and peers

Gilead Sciences (GILD) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Foster City, California.

It was founded in 1987 and joined the S&P 500 on July 1, 2004.

Its fiscal year ends in December, and its shares trade on the Nasdaq.

In its SEC filings it is classified as “Biological Products, (No Diagnostic Substances)”.

Gilead Sciences at a glance

Revenue (12 months): $30.5B
Revenue growth: +5.5%
Operating margin: -8.2%
Net income (12 months): −$3.2B
Free cash flow (12 months): $12.9B
Cash: $3.2B
Debt: $26.2B
Diluted EPS (12 months): $-2.67

Twelve months to June 30, 2026, from the 10-Q filed August 6, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, Gilead Sciences reported revenue of $30.5 billion, about the same as a year earlier (+5.5%).

Its operating margin was -8.2%, down 36.1 percentage points from a year earlier: for every $100 of sales, about $0 was left as operating profit.

Gilead Sciences reported a net loss of $3.2 billion over the period.

Profit fell while sales grew, which usually points to higher costs, heavier investment or one-time items. The filings explain which.

Operating cash flow was $13.6 billion and capital spending $609 million, leaving free cash flow of $12.9 billion (42.5% of revenue).

At the end of the period it held $3.2 billion in cash and $26.2 billion in debt, a net debt position of $23.1 billion.

Five-year trend

Revenue went from $24.7 billion in fiscal 2020 to $29.4 billion in fiscal 2025, about 3.6% a year.
Operating margin widened from 16.5% to 34.0% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$27.3B	$27.3B	$27.1B	$28.8B	$29.4B
Revenue growth	10.6%	-0.1%	-0.6%	6.0%	2.4%
Operating margin	36.3%	26.9%	28.0%	5.8%	34.0%
Net income	$6.2B	$4.6B	$5.7B	$480M	$8.5B
Free cash flow	$10.8B	$8.3B	$7.4B	$10.3B	$9.5B
Diluted EPS	$4.93	$3.64	$4.50	$0.38	$6.78

Fiscal years as reported in Gilead Sciences’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed August 6, 2026 — quarterly report
8-K filed August 4, 2026 — Earnings results
8-K filed May 20, 2026 — Material agreement; New debt obligation
10-Q filed May 7, 2026 — quarterly report
8-K filed May 7, 2026 — Earnings results
8-K filed May 4, 2026 — Shareholder vote results
8-K filed April 28, 2026 — Regulation FD disclosure; Other event

All Gilead Sciences filings on SEC EDGAR

Companies like Gilead Sciences

Other S&P 500 companies in Biotechnology:

More from Health Care

All 60 Health Care companies →

Questions about Gilead Sciences

Is Gilead Sciences's revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $30.5 billion, up 5.5% from a year earlier, according to its SEC filings.

Is Gilead Sciences profitable?

Not over the latest twelve months: it reported a net loss of $3.2 billion for the period to June 30, 2026.

Does Gilead Sciences have more cash or more debt?

At June 30, 2026 it had $3.2 billion in cash and $26.2 billion in debt, so more debt than cash.

When did Gilead Sciences last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on August 6, 2026.

Which companies are similar to Gilead Sciences?

In the S&P 500, Gilead Sciences is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Incyte (INCY), Moderna (MRNA) are in the same group.

Understand the numbers

Source: Gilead Sciences’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.